摘要
目的：从药物经济学角度对紫杉醇联合卡铂或表柔比星两种转移性乳腺癌化疗方案进行分析，为临床用药提供参考。方法：采用成本-效果分析法对TP、TE（T：紫杉醇，P：卡铂，E：表柔比星）两种方案进行临床病例的回顾性分析比较。结果：中位随访期为23.5（9～42）个月，TP、TE两组方案的有效率分别为78.33%和80.00%；1年、2年无进展生存率分别为43.6%和38.9%、10.8%和17.4%；1年、2年总生存率分别为80.3%和78.3%、53.2%和47.9%，两组之间无统计学差异（P〉0.05）。成本-效果分析结果表明，两方案治疗成本分别为10303.8元和13853.3元，成本/效果比分别为131.54和173.17（P〈0.01）。化疗不良反应方面，TP组脱发发生率明显低于TE组（P〈0.01）。结论：两方案近期与远期疗效相当，TP方案成本-效果高于TE方案，可作为晚期乳腺癌的优选方案之一。
Objective：This study evaluated the economical effects of two different regimens for metastatic breast cancer, namely, paclitaxel plus either carboplatin （TP） or epirubicin （TE）. Methods：The cost-effectiveness method in pharmacoeconomics was adopted to analyze retrospectively the two different regimens. Results：The median follow up was 23.5 （range：9 to 42） months. The overall response rate for TP and TE were 78.33%and 80.00%, respectively. The 1-and 2-year progression-free survival rates of TP and TE were 43.6%and 38.9%and 10.8%and 17.4%, respectively. The 1-and 2-year overall survival rates were 80.3%and 78.3%, respectively for TP, whereas the corresponding values for TE were 53.2%and 47.9%. No statistically significant difference was found between the two groups （P〉0.05）. Cost-effectiveness analysis showed that the average costs of the TP and TE regimens were 10 303.8 and 13 853.3 yuan, respectively, with corresponding cost-effectiveness ratios of 131.54 and 173.17 （P〈0.01）. For the chemotherapy toxicity, the alopecia reactions of the TP group were significantly lower than those of the TE group （P〈0.01）. Conclusion：The short-and long-term efficacies of the two regimens were similar. TP regimen was the optimal scheme for advanced metastatic breast cancer.
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2013年第19期1160-1164,共5页
Chinese Journal of Clinical Oncology
基金
天津市重大课题专项项目(编号:12ZCDZSY16200)资助~~
关键词
转移性乳腺癌
紫杉醇
卡铂
表柔比星
成本-效果分析
metastatic breast cancer, paclitaxel, carboplatin, epirubicin, cost-effectiveness analysis
